Leukemia & Lymphoma
Leukemia & Lymphoma Society
Type of Organization: Foundation
Email Address: researchprograms@lls.org
Funds Available for Clinical Trials:
✗ Research:
✔
Applications close 2025-01-30
Funding Details
Requirements: The application will require a Principal Investigator who is responsible for proposal
submission and conduct of the study, including adherence to all stipulations made by LLS
in this document, and in the Funding Agreement, if funded. Study teams may also include
one or two Co-Principal Investigator(s) and multiple Co-Investigators.
LLS welcomes Principal Investigators at all stages of their careers, as well as Principal
Investigators who have not previously conducted research in the area of blood cancer.
However, if the Principal Investigator is an early career investigator, a more
experienced Co-Principal Investigator is required. Principal Investigator(s) must meet
the following eligibility criteria:
• The Principal Investigator must be affiliated with a public or nonprofit institution
(tax exempt under Section 501(c)(3) of the Internal Revenue Code).
• The sponsoring institution must be based in the United States or its territories.
• The Principal Investigator must have a PhD, MD, DO, ScD, JD, or equivalent
doctoral degree.
Page 3
The Principal Investigator and other study team members may come from a variety of
disciplines, including but not limited to medicine/oncology, nursing, social work, public
health, health services research, economics, sociology, health communication,
epidemiology, and biostatistics. We strongly encourage multi-disciplinary teams.
Consistent with LLS’s commitment to diversity, equity, and inclusion, we encourage
applications that have investigators and/or research team members from backgrounds
historically underrepresented in research disciplines as a result of their race, ethnicity,
socioeconomic status, disability, or other factors.
Other info: The Leukemia & Lymphoma Society’s (LLS) Equity in Access Research Program was created to help ensure more equitable access to care for blood cancer patients and survivors.